Clinical trial
RAPAMYCIN FOR KIDNEY ANGIOMYOLIPOMAS
NCT00126672 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00126672 |
|---|---|
| Title | RAPAMYCIN FOR KIDNEY ANGIOMYOLIPOMAS |
| Official title | A Phase II Multi-Center Study of Rapamycin for Treating Kidney Angiomyolipomas in TSC or LAM Patients |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | National Cancer Institute (NCI) NIH Wyeth is now a wholly owned subsidiary of Pfizer Industry Tuberous Sclerosis Alliance |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Nonmalignant Neoplasm, Tuberous Sclerosis, Lymphangioleimyomatosis, Kidney Angiomyolipoma |
| Intervention type | Drug |
| Interventions | Rapamycin |
| Enrollment | 36 |
| Start date | Dec 20, 2005 |
| Primary completion | Apr 1, 2010 |
| Completion | Apr 1, 2010 |
| First posted | Aug 4, 2005 |
| Last update posted | Apr 25, 2022 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: